Novo Nordisk: diabetes drug cuts blood glucose; body weight

(CercleFinance.com) - Novo Nordisk's oral semaglutide has showed statistically significant reductions in blood glucose and body weight in people with long-term type-2 diabetes treated with insulin, the Danish company said.


The American Diabetes Association (ADA) treatment target of HbA1c below 7% was achieved by 36%, 47% and 64% of people treated with 3, 7 and 14 mg oral semaglutide respectively, compared to 10% of people treated with placebo at week 52, the company said.

In the 52-week phase 3a trial comparing oral semaglutide carried out with 731 patients, people treated with the three different doses experienced few and comparable levels of severe or blood glucose-confirmed hypoglycaemic episodes compared to placebo, it said.

The Novo Nordisk shares listed on Nasdaq Nordic are currently up 2.3% on this news.

Copyright (c) 2018 CercleFinance.com. All rights reserved.